Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Recurrent Prostate Cancer
NCT01786265Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2013
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I) in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2013; status: active, not recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01786265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01786265.